Verona Pharma Acquisition Nears Final Approval as Market Awaits Completion

The pharmaceutical sector is closely monitoring the impending acquisition of Verona Pharma by industry giant Merck & Co., a transaction valued at approximately $10 billion. Market activity indicates near-certainty regarding the deal’s completion, with Verona’s share price trading consistently near the agreed acquisition price in recent sessions. This stability suggests investors perceive minimal risk of the arrangement falling through.

Merck has taken concrete steps to solidify the acquisition, successfully placing $6 billion in bonds late last week to secure the necessary financing. This decisive move underscores the company’s commitment to the transaction, which is anticipated to finalize in the fourth quarter of 2025. The agreed-upon terms set the purchase price at $107 per American Depositary Share (ADS) of Verona Pharma.

Breakthrough Read more...